Feed

Eli Lilly

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.